ArticleStem cell research & therapy2025
Differential effects of fetal bovine serum and human platelet lysate on mesenchymal stromal cell-mediated support of hematopoietic stem/progenitor cells: a functional and transcriptomic analysis.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Psoralen Promotes Direct Chemical Reprogramming of Mouse Embryonic Fibroblasts into Osteoblast-like Cells.Pharmaceutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundUmbilical cord blood (UCB) is a valuable source of hematopoietic stem and progenitor cells (HSPC) for transplantation. However, limited cell numbers require ex vivo expansion for effective treatment of adult patients. Mesenchymal stromal cell (MSC)-based co-cultures offer a supportive environment for HSPC expansion and a model to study niche interactions. Human platelet lysate (hPL) provides a xeno-free alternative to fetal bovine serum (FBS) for MSC culture, but its effect on MSC hematopoietic support remains unclear. This study investigates transcriptomic and functional changes induced by hPL-based culture and their impact on HSPC regulation.
methodsMSC from three bone marrow donors were expanded using hPL- or FBS-supplemented media under three regimens: continuously in cell isolation medium (Direct), adapted from the isolation medium to the other formulation (Adapted), or re-adapted back to the isolation medium (Re-adapted). Co-cultures with UCB-derived CD34
resultsMSC properties were reversibly affected by the culture medium. Comparison of hPL-MSC and FBS-MSC revealed 13% differentially expressed genes (DEG), predominantly involved in extracellular matrix organization, chemokine signaling, and cell-cell communication. Minimal transcriptomic variation (1-2% DEG) was observed between Direct and Adapted/Re-adapted MSC. Co-culture with hPL-MSC resulted in significantly lower CD34
conclusionsMSC cultured in hPL- or FBS-supplemented media display significant and reversible transcriptomic differences impacting HSPC expansion. Medium adaptation rapidly reprograms MSC phenotype and gene expression, highlighting responsiveness to environmental cues. Differential expression of key hematopoietic regulatory genes supports the observed functional disparities. These results provide a mechanistic basis for MSC-mediated HSPC support and lay groundwork for optimizing xeno-free expansion systems for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.